Preventive Treatment Health Care Act aims to address chronic weight disease in California by increasing access to antiobesity medications.

The Preventive Treatment Health Care Act seeks to combat chronic weight disease in California by enhancing access to glucagon-like peptide-1 (GLP-1) antiobesity medications. The California Health and Human Services Agency is authorized to form partnerships to increase competition, lower prices, and address supply shortages for these medications. The act also aims to negotiate pricing at or below the cost to Medi-Cal beneficiaries in 2025.

Preventive Treatment Health Care Act aims to address chronic weight disease in California by increasing access to antiobesity medications.

The Preventive Treatment Health Care Act seeks to combat chronic weight disease in California by enhancing access to glucagon-like peptide-1 (GLP-1) antiobesity medications. The California Health and Human Services Agency is authorized to form partnerships to increase competition, lower prices, and address supply shortages for these medications. The act also aims to negotiate pricing at or below the cost to Medi-Cal beneficiaries in 2025.